OCUL vs ZBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ZBIO Captures Institutional Edge (2โ1 Pillars ยท 4โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while OCUL counters with relative strength in Growth & Margin. Fundamentally, OCUL trades at N/M Forward P/E with -680.9% operating margin (-11.5% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, OCUL sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | OCUL Revenue | ZBIO Revenue | OCUL Op. Margin | ZBIO Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -2970.8% | N/A | OCUL |
| FY2019 | $0M | N/A | -2029.9% | N/A | OCUL |
| FY2020 | $20M | N/A | -361.1% | N/A | OCUL |
| FY2021 | $40M | N/A | -179.3% | N/A | OCUL |
| FY2022 | $50M | N/A | -152.7% | N/A | OCUL |
| FY2023 | $60M | $50M | -141.0% | -74.3% | ZBIO |
| FY2024 | $60M | $10M | -269.6% | -3277.8% | OCUL |
| FY2025 | $50M | $10M | -519.8% | -3830.6% | OCUL |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | OCUL | ZBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.4B | $1.9B | Larger Scale | ZBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -11.5% | -100.0% | Higher Growth | OCUL |
| Operating Margin (TTM) Profitability | -680.9% | -2747.5% | Higher Margin | OCUL |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -93.5% | -265.1% | Higher ROE | OCUL |
| 52-Week Range Position Momentum | 1% ($6โ$16) | 46% ($14โ$45) | Stronger Trend | ZBIO |
| Beta / 30D Volatility Risk Regime | 1.69ฮฒ ยท 68% Vol | 1.16ฮฒ ยท 59% Vol | Lower Realized Risk | ZBIO |
| Unified Institutional Score Composite Signal | 45.2 / 100 (HOLD) | 49.4 / 100 (HOLD) | Higher Composite | ZBIO |